Claudio Bordignon

Claudio Bordignon's AcademicInfluence.com Rankings

Claudio Bordignon

Biology

#13604

World Rank

#17158

Historical Rank

Immunology

#945

World Rank

#969

Historical Rank

biology Degrees

Download Badge

Biology

Claudio Bordignon's Degrees

PhD Biological Sciences University of Padua

Why Is Claudio Bordignon Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Claudio Bordignon's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. (1997) (1190)
Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning (2002) (1143)
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy (2013) (1030)
Gene therapy (1993) (1001)
Gene therapy for immunodeficiency due to adenosine deaminase deficiency. (2009) (926)
Type 1 T regulatory cells (2001) (888)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells (2018) (799)
Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs (2006) (760)
Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients (1995) (759)
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. (2009) (446)
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. (2013) (430)
Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer (2012) (424)
CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. (2013) (276)
Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. (2004) (273)
Tumor-mediated liver X receptor-α activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses (2010) (270)
Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy. (2007) (253)
Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines (2002) (213)
A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. (2001) (212)
Wiskott-Aldrich syndrome protein regulates lipid raft dynamics during immunological synapse formation. (2002) (211)
Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. (2002) (210)
Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement (2002) (209)
The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. (2007) (206)
Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells (2006) (202)
Peripheral Blood Lymphocytes as Target Cells of Retroviral Vector-Mediated Gene Transfer (1994) (201)
In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice (2001) (199)
Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. (2006) (196)
Herpes simplex virus thymidine kinase gene transfer for controlled graft-versus-host disease and graft-versus-leukemia: clinical follow-up and improved new vectors. (1998) (189)
A T-cell epitope encoded by a subset of HLA-DPB1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation. (2003) (185)
Robust in vivo gene transfer into adult mammalian neural stem cells by lentiviral vectors. (2004) (175)
Loss of mismatched HLA in leukemia after stem-cell transplantation. (2009) (175)
Expression of human adenosine deaminase in nonhuman primates after retrovirus-mediated gene transfer (1987) (173)
Chemotactic activity of recombinant human granulocyte colony-stimulating factor. (1988) (173)
Antitumor effects of HSV-TK-engineered donor lymphocytes after allogeneic stem-cell transplantation. (2007) (171)
Safety of retroviral gene marking with a truncated NGF receptor (2003) (168)
IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. (2009) (165)
Dendritic cells acquire the MAGE-3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. (2000) (162)
Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. (2003) (158)
Translation of a Retained Intron in Tyrosinase-related Protein (TRP) 2 mRNA Generates a New Cytotoxic T Lymphocyte (CTL)-defined and Shared Human Melanoma Antigen Not Expressed in Normal Cells of the Melanocytic Lineage (1998) (156)
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. (2002) (156)
The oxysterol–CXCR2 axis plays a key role in the recruitment of tumor-promoting neutrophils (2013) (153)
Anti-leukemia potential of interleukin-2 activated natural killer cells after bone marrow transplantation for chronic myelogenous leukemia. (1990) (150)
Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo modulation of donor anti-tumor immunity after allogeneic bone marrow transplantation. (1995) (148)
Comparison between cationic polymers and lipids in mediating systemic gene delivery to the lungs (1999) (148)
De novo design of a tumor-penetrating peptide. (2013) (139)
In vivo tracking of T cells in humans unveils decade-long survival and activity of genetically modified T memory stem cells (2014) (139)
The suicide gene therapy challenge: how to improve a successful gene therapy approach. (2007) (138)
Biodistribution and transgene expression with nonviral cationic vector/DNA complexes in the lungs (2000) (136)
Human CD34(+) cells express CXCR4 and its ligand stromal cell-derived factor-1. Implications for infection by T-cell tropic human immunodeficiency virus. (1999) (135)
Coronaviridae and SARS-associated Coronavirus Strain HSR1 (2004) (134)
Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. (2003) (130)
Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. (2005) (125)
Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. (2008) (124)
Lentiviral vector-mediated gene transfer in T cells from Wiskott-Aldrich syndrome patients leads to functional correction. (2004) (118)
Cell therapy: achievements and perspectives. (1999) (116)
Generation of human memory stem T cells after haploidentical T-replete hematopoietic stem cell transplantation. (2015) (112)
An in vivo model of somatic cell gene therapy for human severe combined immunodeficiency. (1991) (112)
Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma. (2010) (108)
Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors (2014) (106)
Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants (1989) (106)
Improving the safety of cell therapy with the TK-suicide gene (2015) (98)
Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation (2014) (89)
Acquisition of intact allogeneic human leukocyte antigen molecules by human dendritic cells. (2000) (88)
Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: II. In vitro analyses of host effector mechanisms. (1989) (87)
Ex vivo gene therapy with lentiviral vectors rescues adenosine deaminase (ADA)-deficient mice and corrects their immune and metabolic defects. (2006) (85)
Graft failure after T-cell-depleted human leukocyte antigen identical marrow transplants for leukemia: I. Analysis of risk factors and results of secondary transplants. (1989) (85)
Expression of the mage gene family in primary and metastatic human breast cancer: Implications for tumor antigen‐specific immunotherapy (1995) (83)
Phase Ib study of NGR–hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours (2009) (81)
Peripheral blood lymphocytes as target cells of retroviral vector-mediated gene transfer. (1994) (80)
Characterization of natural peptide ligands for HLA-B*4402 and -B*4403: implications for peptide involvement in allorecognition of a single amino acid change in the HLA-B44 heavy chain. (1994) (79)
Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory (2015) (78)
Structural Basis for the Interaction of isoDGR with the RGD-binding Site of αvβ3 Integrin* (2008) (77)
Altered intracellular and extracellular signaling leads to impaired T-cell functions in ADA-SCID patients. (2008) (72)
Reversal of diabetes in mice by implantation of human fibroblasts genetically engineered to release mature human insulin. (1999) (72)
A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease. (2005) (69)
Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif. (2008) (69)
Evaluation of recombinant human erythropoietin to facilitate autologous blood donation before surgery in anaemic patients with cancer of the gastrointestinal tract (1995) (67)
Retroviral vector-mediated high-efficiency expression of adenosine deaminase (ADA) in hematopoietic long-term cultures of ADA-deficient marrow cells. (1989) (67)
Inhibition of natural killer activity by human bronchoalveolar macrophages. (1982) (65)
Stem-cell therapies for blood diseases (2006) (65)
Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line. (1996) (64)
Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. (2010) (64)
Changes in the immune responses against human herpesvirus-8 in the disease course of posttransplant Kaposi sarcoma. (2008) (63)
Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. (1999) (62)
Transfer of the ADA gene into bone marrow cells and peripheral blood lymphocytes for the treatment of patients affected by ADA-deficient SCID. (1993) (59)
Cell-surface marking of CD(34+)-restricted phenotypes of human hematopoietic progenitor cells by retrovirus-mediated gene transfer. (1997) (58)
Extracellular NGFR Spacers Allow Efficient Tracking and Enrichment of Fully Functional CAR-T Cells Co-Expressing a Suicide Gene (2018) (57)
Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation. (2005) (55)
Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours. (2010) (55)
Frequency and targeted detection of HLA-DPB1 T cell epitope disparities relevant in unrelated hematopoietic stem cell transplantation. (2007) (51)
T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation. (2012) (51)
Therapeutic applications for hematopoietic stem cell gene transfer (2002) (50)
Peripheral blood lymphocytes genetically modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in cancer patients. (2009) (49)
Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors (2011) (47)
Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. (1997) (47)
Corrigendum: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs (2013) (45)
Peripheral blood stem cell allograft rejection mediated by CD4+ T lymphocytes recognizing a single mismatch at HLA-DPβ1*0901 (2001) (43)
Natural cytotoxicity on tumour cells of human macrophages obtained from diverse anatomical sites. (1980) (43)
RD2-MolPack-Chim3, a packaging cell line for stable production of lentiviral vectors for anti-HIV gene therapy. (2013) (42)
Human insulin production and amelioration of diabetes in mice by electrotransfer-enhanced plasmid DNA gene transfer to the skeletal muscle (2002) (41)
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy. (2010) (41)
Phase I Clinical and Magnetic Resonance Imaging Study of the Vascular Agent NGR-hTNF in Patients with Advanced Cancers (European Organization for Research and Treatment of Cancer Study 16041) (2010) (41)
IL-7 receptor expression identifies suicide gene-modified allospecific CD8+ T cells capable of self-renewal and differentiation into antileukemia effectors. (2011) (41)
Gene therapy for adenosine deaminase deficiency (2003) (40)
Natural cytotoxic activity in human lungs. (1982) (40)
The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer (2019) (39)
Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT. (2012) (39)
Transfer of the ADA gene into human ADA-deficient T lymphocytes reconstitutes specific immune functions. (1992) (39)
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients (2012) (38)
Hematopoietic histoincompatibility reactions by NK cells in vitro: model for genetic resistance to marrow grafts. (1985) (38)
MAGE, BAGE and GAGE genes experiences in fresh epithelial ovarian carcinomas (1996) (37)
Absence of Metabolic Cross-correction in Tay-Sachs Cells (2002) (36)
R-CHOP preceded by blood-brain barrier permeabilization with engineered tumor necrosis factor-α in primary CNS lymphoma. (2019) (36)
Cytotoxicity on tumour cells of human mononuclear phagocytes: defective tumoricidal capacity of alveolar macrophages. (1980) (36)
Th22 cells increase in poor prognosis multiple myeloma and promote tumor cell growth and survival (2015) (35)
CD 44 v 6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma (2013) (35)
Selected natural and synthetic retinoids impair CCR7‐ and CXCR4‐dependent cell migration in vitro and in vivo (2008) (34)
A family of rapidly evolving genes from the sex reversal critical region in Xp21 (1995) (34)
2D TR-NOESY experiments interrogate and rank ligand-receptor interactions in living human cancer cells. (2010) (32)
Peripheral blood stem cell allograft rejection mediated by CD4(+) T lymphocytes recognizing a single mismatch at HLA-DP beta 1*0901. (2001) (32)
Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro. (2001) (32)
24-Hydroxycholesterol participates in pancreatic neuroendocrine tumor development (2016) (31)
Abrogation of Prostaglandin E2/EP4 Signaling Impairs the Development of rag1+ Lymphoid Precursors in the Thymus of Zebrafish Embryos1 (2007) (30)
The administration of drugs inhibiting cholesterol/oxysterol synthesis is safe and increases the efficacy of immunotherapeutic regimens in tumor-bearing mice (2016) (30)
Human mononuclear phagocytes from different anatomical sites differ in their capacity to metabolize arachidonic acid. (1984) (30)
CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice (2020) (30)
Tracking Genetically Engineered Lymphocytes Long-Term Reveals the Dynamics of T-Cell Immunological Memory (2015) (30)
Restoration of the GM2 Ganglioside Metabolism in Bone Marrow–Derived Stromal Cells from Tay-Sachs Disease Animal Model (2002) (29)
Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma (2010) (29)
Complete generic and extensive fine-specificity typing of the HLA-B locus by the PCR-SSOP method. (1995) (27)
Lymphocytes genetically modified to express tumor antigens target DCs in vivo and induce antitumor immunity. (2007) (27)
Pre-transplant 18FDG-PET predicts outcome in lymphoma patients treated with high-dose sequential chemotherapy followed by autologous stem cell transplantation (2008) (25)
HLA-A*02 subtype distribution in Caucasians from northern Italy: identification of A*0220. (1996) (25)
Expression and purification of a human, soluble Arylsulfatase A for Metachromatic Leukodystrophy enzyme replacement therapy. (2005) (25)
The DAM gene family encodes a new group of tumor-specific antigens recognized by human leukocyte antigen A2-restricted cytotoxic T lymphocytes. (1998) (24)
MAGE BAGE and GAGE genes expression in fresh epithelial ovarian carcinomas. (1996) (24)
A dual role for genetically modified lymphocytes in cancer immunotherapy. (2012) (24)
Metabolic correction in oligodendrocytes derived from metachromatic leukodystrophy mouse model by using encapsulated recombinant myoblasts (2007) (24)
RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope (2016) (24)
Therapeutic and diagnostic applications of minor histocompatibility antigen HA-1 and HA-2 disparities in allogeneic hematopoietic stem cell transplantation: a survey of different populations. (2006) (22)
Selective expression of fos proto-oncogene in human acute myelomonocytic and monocytic leukemias: a molecular marker of terminal differentiation. (1987) (22)
Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with leukemic APCs and modified with a suicide gene. (2013) (21)
Potential and limitations of HSV-TK-transduced donor peripheral blood lymphocytes after allo-BMT. (1997) (21)
Clinical and immunologic responses in melanoma patients vaccinated with MAGE‐A3‐genetically modified lymphocytes (2013) (20)
Soybean Lectin Agglutination and E-Rosette Depletion for Removal of T-Cells from HLA-Identical Marrow Grafts: Results in 60 Consecutive Patients Transplanted for Hematologic Malignancy (1986) (19)
Improving the antitumor activity of R-CHOP with NGR-hTNF in primary CNS lymphoma: final results of a phase 2 trial. (2020) (18)
Suicide Gene Transduced T‐cells for the Regulation of the Graft‐versus‐Leukemia Effect (1998) (18)
Phase I and pharmacodynamic study of high-dose NGR–hTNF in patients with refractory solid tumours (2011) (17)
IL-3 or IL-7 increases ex vivo gene transfer efficiency in ADA-SCID BM CD34+ cells while maintaining in vivo lymphoid potential. (2004) (17)
Restoration of bacterial killing activity of human respiratory cystic fibrosis cells through cationic vector-mediated cystic fibrosis transmembrane conductance regulator gene transfer. (1999) (17)
Transduced fibroblasts and metachromatic leukodystrophy lymphocytes transfer arylsulfatase A to myelinating glia and deficient cells in vitro. (1998) (17)
Mobilized blood CD34+ cells transduced and selected with a clinically applicable protocol reconstitute lymphopoiesis in SCID-Hu mice. (2004) (16)
Characterization of the in vitro sensitivity of human lymphoid and hematopoietic progenitors to L-leucyl-L-leucine methyl ester. (1991) (15)
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies (2010) (15)
Progress and prospects: graft-versus-host disease (2010) (15)
Differential expression of HLA-A*02 subtypes in Colombian Blacks and Mestizos. (2008) (15)
Optimisation of retroviral supernatant production conditions for the genetic modification of human CD34+ cells (2001) (14)
Codon Optimization Leads to Functional Impairment of RD114-TR Envelope Glycoprotein (2017) (14)
Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors (2008) (14)
Graft failures after T cell depleted marrow transplants for leukemia: clinical and in vitro characteristics. (1987) (14)
Phase I-IIa Clinical Trial to Assess Safety and Efficacy of MLM-CAR44.1, a CD44v6 Directed CAR-T in Relapsed/Refractory Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) (2018) (14)
Vectofusin-1 Promotes RD114-TR-Pseudotyped Lentiviral Vector Transduction of Human HSPCs and T Lymphocytes (2017) (13)
NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells (2013) (12)
A new chance for SCID gene therapy (1998) (12)
35th Annual meeting of the European Association for the Study of Diabetes. Brussels, Belgium, 28 September-2 October, 1999. Abstracts. (1999) (11)
Early recovery of CMV immunity after HLA-haploidentical hematopoietic stem cell transplantation as a surrogate biomarker for a reduced risk of severe infections overall (2015) (11)
Sequencing of a new HLA-A*32 subtype (A*3202) (1996) (11)
A novel human packaging cell line with hematopoietic supportive capacity increases gene transfer into early hematopoietic progenitors. (2001) (11)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells (2018) (10)
Changes in T-cell responses against human herpesvirus-8 correlate with the disease course of iatrogenic Kaposi's sarcoma in a patient with undifferentiated arthritis. (2009) (10)
Gene therapy: efforts at developing large animal models for autologous bone marrow transplant and gene transfer with retroviral vectors. (1987) (10)
Molecular purging of multiple myeloma cells by ex-vivo culture and retroviral transduction of mobilized-blood CD34+ cells (2007) (10)
Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF (2015) (10)
The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms (2015) (9)
Long-Term Safety and Efficacy of Gene Therapyfor Adenosine Deaminase (ADA)-Deficient Severe Combined Immunodeficiency (2009) (9)
Suicide-Gene-Transduced Donor T-Cells for Controlled Graft-versus-Host Disease and Graft-Versus-Tumor (2002) (9)
Factors affecting the unexpected failure of DCE-MRI to determine the optimal biological dose of the vascular targeting agent NGR-hTNF in solid cancer patients. (2011) (9)
Phase III trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC in previously treated patients with advanced malignant pleural mesothelioma (MPM). (2015) (9)
The Role of Residual Host Immunity in Graft Failures following T‐cell‐depleted Marrow Transplants for Leukemia a (1987) (8)
Immunomodulatory Drugs in the Context of Autologous Hematopoietic Stem Cell Transplantation Associate With Reduced Pro-tumor T Cell Subsets in Multiple Myeloma (2019) (8)
CD44v6 Is Required For In Vivo Tumorigenesis Of Human AML and MM Cells: Role Of Microenvironmental Signals and Therapeutic Implications (2013) (7)
Cancer Therapy : Clinical Phase I Study of NGR-hTNF , a Selective Vascular Targeting Agent , in Combination with Cisplatin in Refractory Solid Tumors (2011) (7)
Rapid and Wide Immunereconstitution Obtained with HSV-TK Engineered Donor Lymphocyte Add-Backs Permits Long-Term Survival after haplo-HSCT. (2006) (7)
Radiosensitivity of NK lytic activities and NK-mediated hematopoietic colony inhibition: effect of activation with IL-2 and blocking of the T-200 molecule. (1988) (7)
MODULATION OF NK ACTIVITY BY HUMAN MONONUCLEAR PHAGOCYTES: SUPPRESSIVE ACTIVITY OF BRONCHO-ALVEOLAR MACROPHAGES (1982) (7)
Erratum: Tracking genetically engineered lymphocytes long-term reveals the dynamics of T cell immunological memory (Science Translational Medicine (2015) 7:319 (319er9)) (2015) (6)
Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT (2016) (6)
Phase II trial of NGR-hTNF and doxorubicin in relapsed small cell lung cancer (SCLC). (2011) (6)
Gene therapy in Europe. (1995) (6)
Co-Expression of a Suicide Gene in CAR-Redirected T Cells Enables the Safe Targeting of CD44v6 for Leukemia and Myeloma Eradication (2012) (6)
Phase I and DCE-MRI evaluation of NGR-TNF, a novel vascular targeting agent, in patients with solid tumors (EORTC 16041) (2008) (6)
Follow-up study on PCR-SSOP typing of the HLA-A locus: improved resolution of A-10 and A-19 splits. (1996) (5)
Tumoricidal and immunoregulatory activity of macrophages from human ovarian carcinomas. (1982) (5)
Human proinsulin production in primary rat hepatocytes after retroviral vector gene transfer (1999) (5)
Molecular characterization of HLA class I in Colombians carrying HLA-A2: high allelic diversity and frequency of heterozygotes at the HLA-B locus. (1999) (5)
Haploidentical HSCT: a 15-year experience at San Raffaele (2015) (5)
Genomic Loss of the Mismatched HLA Locus in Leukemia Is a Major Mechanism of in Vivo Escape from T Cell Immunosurveillance Following Haploidentical HSCT (2008) (5)
1107. Gene Therapy Clinical Trials for Relapsed Leukemia with Infusions of the Suicide-Gene Transduced Donor Lymphocytes in Japan (2006) (4)
Infusion of Donor Lymphocytes Genetically Engineered to Express the Herpes Simplex Virus Thymidine Kinase (HSV-TK) Suicide Gene after Haploidentical Hematopoietic Stem Cell Transplantation (HSCT): Preliminary Efficacy Data from the Randomized TK008 Study (2014) (4)
Loss of Mismatched HLA as a Mechanism of Leukemia Immune Escape in Family Haploidentical and Unrelated HSCT: Analysis of 103 Transplants From Alternative Donors. (2009) (4)
NGR and isoDGR are separate moieties binding to different receptors. (2009) (4)
Two doses of NGR-hTNF (N) given alone or in combination with doxorubicin (D) in soft tissue sarcomas (STS). (2013) (4)
NGR-hTNF in previously treated patients with malignant pleural mesothelioma (MPM) . (2011) (4)
Unplugging the T cell receptor (2003) (4)
Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM). (2009) (3)
Relationships of peripheral blood lymphocyte counts (PBLC) with antitumor activity of NGR-hTNF given in combination with chemotherapy (CT). (2013) (3)
35th Annual Meeting of the European Association for the Study of Diabetes (2016) (3)
Clonal Analyses of Retroviral Vector Integrations in ADA-SCID Patients Treated with Stem Cell Gene Therapy. (2006) (3)
A phase I study to define the optimal low dose of NGR-hTNF, a novel vascular targeting agent (VTA), in combination with cisplatin in patients (pts) with solid tumors (2008) (3)
Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) refractory to standard regimens. (2009) (3)
AT-cell epitope encoded by a subset of HLA-DPB 1 alleles determines nonpermissive mismatches for hematologic stem cell transplantation (2004) (3)
Dual Transgenesis of T Cells with a Novel CD44v6-Specific Chimeric Antigen Receptor and a Suicide Gene for Safe and Effective Targeting of Chemoresistance in Hematopoietic Tumors (2011) (3)
NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM): Preliminary results of multicenter phase II study (2008) (3)
Gene Therapy for Severe Combined Immunodeficiencies (1999) (3)
A Phase II Multicenter Trial of HSV-TK Engineered Donor Lymphocytes after Haplo-Identical HSCT: Early Immune Reconstitution and Abrogation of Gvhd. (2004) (3)
Regulation of the Tumoricidal and Suppressive Activity of Human Macrophages (1983) (2)
TCR Gene Editing Results in Effective Immunotherapy of Leukemia without the Development of GvHD (2011) (2)
Extracorporeal Membrane Oxygenation: A New Way to Study Toxic Drugs in Chronic Diseases (2011) (2)
Treatment-free interval (TFI) after first-line therapy as a prognostic and predictive factor in malignant pleural mesothelioma (MPM): Findings from the NGR015 phase III trial with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC. (2015) (2)
An approach to HIV gene therapy by transduction of multifunctional retroviral vectors in primary human T lymphocytes. (1997) (2)
6617 Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients (pts) with advanced hepatocellular carcinoma (HCC) (2009) (2)
The challenge of private biomedical research funding in Italy (1999) (2)
Abstract 2937: Editing central memory T lymphocyte specificity for safe and effective adoptive immunotherapy of leukemia (2010) (2)
Retroviral Vector‐mediated Gene Transfer and Expression in Nonhuman Primates Following Autologous Bone Marrow Transplantation a (1987) (2)
Infusions of HSV-TK Engineered Donor Lymphocytes Effectively Protect Patients Undergoing Haploidentical Stem Cells Trasplantation (HSCT) from Infectious Mortality. (2007) (2)
Incidence, Risk Factors and Clinical Outcome Of Leukemia Relapses Due To Loss Of The Mismatched HLA Haplotype After Partially-Incompatible Hematopoietic Stem Cell Transplantation (2013) (2)
Phase I and pharmacodynamic study of high-dose NGR-hTNF in patients with solid tumors. (2011) (2)
HSV-TK Engineered Donor Lymphocytes Add-Backs Reduce Late Mortality and Improve Survival of High Risk Acute Leukemia after Haplo-HSCT: Results of a Phase II Multicenter Trial. (2005) (2)
Erratum: HLA-A*02 subtype distribution in Caucasians from northern Italy: Identification of A*0220 (Journal of Tissue Antigens(1996)48(673-679) (1997) (2)
Off-Tumor Target Expression Levels Do Not Predict CAR-T Cell Killing: A Foundation For The Safety Of CD44v6-Targeted T Cells (2013) (2)
Erratum: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs (Nature (2013) 494 (506) DOI: 10.1038/nature11976)) (2014) (2)
NGRhTNF, a new vascular targeting agent with a dual mechanism of action: preliminary clinical results. (2006) (2)
NGR-hTNF as second-line treatment in malignant pleural mesothelioma (MPM). (2012) (2)
NGR-hTNF and doxorubicin in relapsed small-cell lung cancer (SCLC). (2012) (2)
GvHD Kinetics after Haploidentical TK-Cells: In-Vivo HSV-TK Suicide Machinery Is Effective in GvHD Control and Provide a Long-Term Immune-Suppressive Treatment-Free Survival (2014) (2)
Randomized phase II trial of NGR-hTNF in combination with standard chemotherapy in previously untreated non-small cell lung cancer (NSCLC). (2013) (2)
T Cell Suicide Gene Therapy Prompts Thymic Renewal in Adults After Haploidentical Hematopoietic Stem Cell Transplantation in the Absence of Post-Transplant Immunesuppression (2011) (2)
Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules. (2000) (1)
3099 Phase 3 trial (NGR015) of best investigator choice (BIC) with or without NGR-hTNF in previously treated malignant pleural mesothelioma (MPM) (2015) (1)
ROLE OF NK CELLS IN HYBRID RESISTANCE TO BONE MARROW GRAFTS1 (1985) (1)
Efficacy of HSV-TK+ suicide gene donor lymphocytes after haploidentical transplantation (haplo-HSCT): Preliminary results of randomized TK008 study. (2014) (1)
reconstitutes specific immune functions Transfer of the ADA gene into human ADA-deficient T lymphocytes (2011) (1)
Temporal, Quantitative and Functional Characteristics of Single-KIR Positive Alloreactive NK Cell Recovery Account for Impaired Graft Versus Leukemia Activity after Haploidentical HSCT. (2007) (1)
NGR-hTNF and doxorubicin in relapsed ovarian cancer (OC). (2012) (1)
Blood-Brain Barrier Permeabilization with Engineered Tumor Necrosis Factor-α Followed by R-CHOP Is an Active and Safe Salvage Therapy in Primary CNS Lymphoma (2020) (1)
Graft Host Interactions Following T-Cell Depleted Marrow Transplants (1989) (1)
A phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041) (2007) (1)
Correction of hyperglycemia in mice by transplantation of cells engineered for the production of fully processed human insulin (1996) (1)
Patient-reported outcomes (PROs) in the double-blind phase 3 trial (NGR015) with NGR-hTNF plus best investigator choice (BIC) versus placebo plus BIC for previously treated patients with malignant pleural mesothelioma (MPM). (2016) (1)
Graft-Versus-Host Disease after Haploidentical Stem Cell Transplantation in High Risk Haematological Diseases: A 10-Years Evaluation at San Raffaele Scientific Institute (2014) (1)
Long-term safety and survival outcomes after TK-expressing donor lymphocyte infusion (TK-DLI) in allogeneic hematopoietic stem cell transplantation (HSCT). (2013) (1)
Immune Reconstitution and Immune Correlates of Clinical Outcome IN Acute LEUKEMIA PATIENTS Treated with Haploidentical STEM CELL TRANSPLANTATION. (2009) (1)
Long-Term Immunological Profile of Patients Treated with Haploidentical HSCT and TK-Cells to Study the Requirements of Memory T Cell Persistence (2014) (1)
NGR-hTNf plus doxorubicin in recurrent ovarian cancer (2012) (1)
From TCR Gene Transfer to TCR Gene Editing of Central Memory T Lymphocytes for Immunotherapy of Leukemia. (2009) (1)
Safety and anticancer activity of low dose regimen of NGRhTNF, a new vascular targeting agent, in solid advanced malignancies (NGR002 phase I trial) (2007) (1)
819. Molecular Follow-Up of Patients Treated with Allogeneic Hematopoietic Stem Cell Transplantation and Donor Lymphocytes Transduced with a Retroviral Vector Expressing HSV-TK and |[Delta]|LNGFR (2005) (1)
540. Vectofusin-1 Significantly Enhances Transduction of Ex-Vivo Activated T Cells With RD114-TR-Pseudotyped Lentiviral Vectors Derived from the RD3-MolPack Stable Packaging Cells (2015) (1)
Naive-Derived Memory Stem T Cells: A Novel Promising Platform for Cancer Immune-Gene Therapy (2012) (1)
Allografting for patients with advanced hematological malignancies: non-myeloablative conditioning followed by the reinfusion of lymphocytes engineered with hsv thymidine kinase gene (2000) (1)
Haploidentical Transplantation Outcome Is Not Inferior to Standard Matched Related and Unrelated Donor Transplantation: An Intention-to-Treat Analysis of 241 Patients with Acute Myeloid Leukemia (2012) (1)
Glucose-induced activity of liver-type pyruvate kinase promoter in primary rat hepatocytes. (1998) (1)
Progress Towards the Clinical Application of Somatic Cell Gene Therapy (1993) (1)
Safety and Efficacy of Donor T Cells Engineered with Herpes Simplex Virus Thymidine-Kinase Suicide Gene (TK Cells) Given after T-Cell Depleted (TCD) Haploidentical Hematopoietic Transplantation (Haplo-HSCT): Results of a 14-Year Follow-Up in 45 Patients (2017) (1)
Phase II study of NGR-hTNF plus doxorubicin in relapsed ovarian cancer (OC). (2011) (1)
9011 NGR-hTNF, a vascular targeting agent (VTA), in previously treated patients with malignant pleural mesothelioma (MPM): a phase II study (2009) (1)
Randomized, phase II trial of NGR-hTNF and chemotherapy in chemotherapy-naive patients with non-small cell lung cancer (NSCLC): Preliminary results. (2011) (1)
A phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in pretreated patients (pts) with advanced hepatocellular carcinoma (HCC) (2008) (1)
Randomized phase II trial of NGR-hTNF with an anthracycline in platinum-refractory or -resistant ovarian cancer (OC). (2014) (1)
Safety and antitumour activity of NGR-hTNF, a selective vascular targeting agent (VTA), administered at low dose in pre-treated patients with hepatocellular carcinoma (HCC): preliminary results of a phase II trial (2008) (1)
Modeling Antileukemic Adoptive Immunotherapy In Mouse-Humans Chimeras To Identify Novel Mechanisms Of Cancer Immunoediting (2013) (1)
Corrigendum: Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs (2014) (1)
Revealing the Generation of Human Memory Stem T Cells in Haploidentical T-Replete Hematopoietic Stem Cell Transplantation (2014) (1)
The in vivo targeting of tumor antigens to DCs by administration of transduced autologous lymphocytes results in robust and prolonged immunization: Pre-clinical validation and results of a pilot clinical studies of vaccination for metastatic melanoma. (2006) (1)
Autoantibody Production during Chronic Graft-Versus-Host Disease Does Not Associate with Long-Term Persistence of Host B Cells in Humans (2008) (1)
Gene Therapy and Apheresis (1993) (1)
Phase Ib study of NGR-hTNF, a selective vascular targeting agent (VTA), in combination with cisplatin in patients with refractory solid tumors. (2009) (1)
130. Purification of Large Scale mRNA Encoding ZFN Nucleases by dHPLC Technology (2016) (1)
9014 POSTER DISCUSSION Randomized Phase II Trial of NGR-hTNF and Chemotherapy in Chemo-naive Patients With Non-small Cell Lung Cancer (NSCLC) -Preliminary Results (2011) (1)
R‐CHOP PRECEDED BY ENGINEERED TUMOR NECROSIS FACTOR (TNF) IN RELAPSED OR REFRACTORY PRIMARY DIFFUSE LARGE B‐CELL LYMPHOMA OF THE CNS (rPCNSL): FINAL RESULTS OF THE INGRID TRIAL (2019) (1)
Feasibility of a Stem Cell Gene Therapy Approach with Nonmyeloablative Conditioning in Patients with HIV-1 Infection. (2004) (1)
Correlation of Infusion-Related Reactions (IRR) and Outcome in Patients Receiving Ngr-Htnf Treatment (2012) (0)
Correction of metachromatic leukodystrophies (MLD) in the mouse model by transplantation of genetically modified hematopoietic stem cells (2004) (0)
P480 - HLA-A rare alleles in Caucasian bone marrow donors identified by molecular analysis (1996) (0)
Long-Term Immunological Profile and T Cell Dynamics In Patients Treated With Allogeneic Transplantation and TK-Cells For Hematological Malignancies (2013) (0)
Suicide Gene (HSVtk) Ablation of Hematopoietic Stem Cells and Their Progeny In the Rhesus Macaque Model: An Approach to Deletion of Dangerous Clones. (2010) (0)
Treatment-free interval (TFI) after first-line therapy (FLT) and disease control rate (DCR) on second-line therapy (SLT): Impact on overall survival (OS) in relapsed malignant pleural mesothelioma (MPM). (2013) (0)
A biological and pharmacologic phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumors (EORTC 16041) (2007) (0)
P15 - Molecular analysis of HLA-A*02 subtype frequencies in the population of northern Italy (1996) (0)
Requirements for Retroviral Targeting of a Suicide Gene to Alloreactive Memory Stem T Cells for Adoptive Immunotherapy of Leukemia. (2007) (0)
41. Ex Vivo Gene Therapy Provides a Unique Therapeutic Benefit and Corrects Metachromatic (MLD) and Globoid (GLD) Leukodystrophy in the Mouse Models (2004) (0)
Impaired GvL Potential of Natural Killer Cells Early Reconstituting Following Haploidentical HSCT. (2006) (0)
Impact of treatment-free interval (TFI) and disease control rate (DCR) on survival outcome in relapsed malignant pleural mesothelioma (MPM). (2014) (0)
209. TCR Gene Editing in a Single Step of T Cell Activation To Redirect T Cell Specificity and Prevent GvHD (2015) (0)
Early Blast Clearance Evaluation after Induction Chemotherapy for Acute Myeloid Leukemia By Multiparameter Flow Cytometry and WT1-RNA Quantification: A Single Center Experience (2014) (0)
Thymic Renewal and Anti-Leukemic Effect In Adults After Haploidentical Transplantation and Donor T Cell Suicide Gene Therapy (2010) (0)
stem cell transplantation depleted - for early immune reconstitution after hematopoietic T-cell Immunologic potential of donor lymphocytes expressing a suicide gene (2013) (0)
Family MAGE Multiple Members of the Identification of a Promiscuous T-Cell Epitope Encoded by Updated (2000) (0)
Non-Linear Clonal Evolution Of Leukemia Driven By Selective Immune Pressure and Revealed By HLA Typing and High-Depth Exome Sequencing (2013) (0)
Gene Marking of T Lymphocytes (1999) (0)
TCR Gene Editing Achieved In a Single Round Of T Cell Activation Is Sufficient To Redirect T Cell Specificity and Prevent GvHD (2013) (0)
Modeling leukemia immunoediting in mouse-human chimeras (P2169) (2013) (0)
Gene transfer in Naive-derived memory stem T-cells: a novel promising platform for cancer immunotherapy (2012) (0)
Muscle-direct gene electrotransfer provides circulating human insulin in mice. (2000) (0)
Molecular Follow-Up of Patients Treated with HSV-TK/ΔLNGFR Engineered Donor Lymphocytes after Allogeneic Stem Cell Transplantation. (2004) (0)
Restoration of arylsulphatase A activity in murine metachromatic leukodistrophy oligodendrocytes by retroviral vector-mediated gene transfer (2000) (0)
Human Herpes Virus-6 and Clinical Manifestations After Allogeneic Hematopoietic Stem Cell Transplantation (2011) (0)
Contribution of NGR and TNF portions of NGR-TNF to tumor vessel-specific homing and apoptosis in vivo. (2010) (0)
Twenty-five years of gene therapy for genetic diseases and leukemia: The road to marketing authorization of the first ex vivo gene therapies. (2017) (0)
Infusion-related reactions (IRR) during NGR-hTNF therapy as potential predictors of clinical outcome. (2013) (0)
Impact of lactate dehydrogenase (LDH) and absolute lymphocyte count (ALC) on outcome of previously treated patients with malignant pleural mesothelioma (MPM) receiving chemotherapy (CT) with or without NGR-hTNF in the phase 3 trial NGR015. (2016) (0)
NEUROPHYSIOLOGICAL STUDY OF GENE THERAPY EFFECT ON MOUSE MODEL OF METACHROMATIC LEUKODYSTROPHY (2002) (0)
Abstract 4249: NGR-TNF, a novel direct-acting vascular targeting agent, does not induce “cytokine-rebound” recruitment of pro-angiogenic bone-marrow derived cells (2011) (0)
972. HSC-Based Ex Vivo Gene Therapy Prolongs Survival and Improves the Phenotype of Globoid Cell Leukodystrophy Mice (2005) (0)
PK-7 and RD2-MolPack-Chim3.14, two packaging cell clones for semi-stable and stable production of HIV-based lentiviral vectors (2010) (0)
Phase II study of NGR-hTNF, a selective vascular targeting agent (VTA), in previously treated patients with hepatocellular carcinoma (HCC). (2016) (0)
Association Between Peripheral Blood Lymphocyte Count (PBLC) and Outcome in Patients with Solid Tumors Treated with Ngr-Htnf (2012) (0)
Loss of Mismatched HLA At Leukemia Relapse After Hematopoietic Stem Cell Transplantation Is Significantly Associated with Clinical and Immunogenetic Hallmarks of Donor-Versus-Host Alloreactivity (2012) (0)
Potential of Gene Therapy in Bone Marrow Transplantation (2012) (0)
Phase I study of NGR-hTNF administered at high doses in refractory patients with solid tumors. (2010) (0)
High Alloreactive Potential of Central Memory T-Lymphocytes Expressing a Suicide Gene for the Cure of Hematologic Malignancies. (2006) (0)
Structural basis for L-isoDGR stereospecific recognition of αvβ3 (2007) (0)
331. Lentivirus-Mediated Ex Vivo Gene Therapy in ADA-Deficient SCID Mice (2005) (0)
non-permissive mismatches for hematological stem cell transplantation A T cell epitope encoded by a subset of HLA-DPB1 alleles determines (2013) (0)
FUNCTIONAL STATUS OF TUMOR-ASSOCIATED EFFECTOR CELLS (1982) (0)
Abstracts of the 8th Meeting of the Italian Peripheral Nerve Study Group: 31: Absract (2003) (0)
HEMATOPOIESIS Human CD34 1 Cells Express CXCR4 and Its Ligand Stromal Cell–Derived Factor-1. Implications for Infection by T-Cell Tropic Human Immunodeﬁciency Virus (1999) (0)
from naive precursors IL-7 and IL-15 instruct the generation of human memory stem T cells (2013) (0)
Vascular effects of the vascular targeting agent NGR-hTNF in patients (pts) with advanced solid cancer: A dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) EORTC study. (2010) (0)
Effect of Related and Unrelated Donor Haemopoietic Stem-Cell Transplantation on Outcome In Adults with High Risk Acute Leukemia: An Intention-to-Treat Analysis at a Single Center Institution (2010) (0)
breast cancer and donor lymphocyte infusions for patients with metastatic renal and Nonmyeloablative conditioning followed by hematopoietic cell allografting (2013) (0)
Genomic and Transcriptional Immunoediting of Acute Myeloid Leukemia in Response to Allogeneic Hematopoietic Stem Cell Transplantation (2011) (0)
Abstract 5081: Development and characterization of a new antiangiogenic peptide targeting tumor vessels. (2013) (0)
Brief Report Mobilized Blood CD34 1 Cells Transduced and Selected with a Clinically Applicable Protocol Reconstitute Lymphopoiesis in SCID-Hu Mice (2004) (0)
Gene Transfer for Immune Therapy of Cancer (1999) (0)
Background and Methods Background and methods Results Randomized phase II trial of NGR-hTNF and chemotherapy in chemo-naïve patients with non-small cell lung cancer (NSCLC): preliminary results (2011) (0)
765. Suicide Gene Therapy by Central Memory Human T Lymphocytes (2006) (0)
366 POSTER Phase I study of NGR-TNF, a novel vascular targeting agent, in patients with refractory solid tumours (EORTC 16041) (2006) (0)
6062 NGR-hTNF, a vascular targeting agent (VTA), administered as single agent in patients (pts) with colorectal cancer (CRC) failing standard regimens: a phase II study (2009) (0)
Receptor Repertoire Reconstitution Suggests Acquisition of Patient-Specific Tolerance by Natural Killer Cells Arising from Hematopoietic Progenitor Stem Cells after Haploidentical Transplantation. (2005) (0)
TK-Cells Safety and Efficacy in Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Clinical and Molecular Assessment in 128 Treated Patients. (2012) (0)
Deoxyadenosine Inhibits T-Cell Activation in ADA-SCID Patients through a cAMP/PKA-Dependent Pathway. (2006) (0)
426. Cure of Established Disease and Direct Evidence of Cellular Cross-Correction in the Nervous System of Metachromatic Leukodystrophy Mice after HSC-Based Gene Therapy (2005) (0)
Relationships between occurrence of chills and clinical outcome during NGR-hTNF therapy. (2014) (0)
Evaluation of NIH-Defined Chronic Graft-Versus-Host-Disease in a Rapamycin-Based Haploidentical Stem Cell Transplantation: Analysis of 113 Consecutive Patients with High Risk Haematological Malignancies (2012) (0)
1228 Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours (2009) (0)
15 Correction of established neurologic disease and evidences of in vivo cross correction in the mouse model of metachromatic leukodystrophy (2007) (0)
allogeneic stem-cell transplantation Antitumor effects of HSV-TKengineered donor lymphocytes after (2010) (0)
Phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) trial of NGR-hTNF given at high doses in patients with refractory solid tumors. (2012) (0)
Lymphoid Precursors in the Thymus of + rag1 Signaling Impairs the Development of /EP4 2 Abrogation of Prostaglandin E (2017) (0)
1004. Integration Analyses in ADA-Deficient SCID Patients Successfully Treated with Stem Cell Gene Therapy (2004) (0)
The infusion of suicide gene-modified donor T cells after hematopoietic stem cell transplantation prompts thymic renewal in adult patients by an IL-7 dependent mechanism (169.4) (2011) (0)
Prognostic and predictive value of neutrophil-to-lymphocyte ratio (NLR) in previously treated patients with malignant pleural mesothelioma (MPM) enrolled in the NGR015 phase 3 trial. (2015) (0)
Retroviral Vector Integration Deregulates Gene Expression but Has No Consequences on the Biology and Function of Transplanted T Cells. (2005) (0)
Amphotropic retrovirus packaging cell line, process for production and use (1999) (0)
A method of immunomodulation by adoptive transfer of antigen-specific cytotoxic T cells (1994) (0)
Leukemic Dendritic Cells Expand Central Memory T Lymphocytes From HCT Donors Able to React against the Original Leukemia in Vitro and In Vivo. (2009) (0)
Zebrafish Embryos Lymphoid Precursors in the Thymus of + rag 1 Signaling Impairs the Development of / EP 42 Abrogation of Prostaglandin E Traversari (2007) (0)
Infusion of suicide gene-modified donor T cells promotes a rapid and effective immune reconstitution and provides long-term survival after haploidentical hemaopoietic cell transplantation for the cure of patients with high-risk leukemia (2008) (0)
Biffi Metachromatic Leukodystrophy Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits (2013) (0)
NY-ESO-1 Single Edited T Cells to Treat Multiple Myeloma without Inducing GvHD (2014) (0)
43-OR: Genomic loss of mismatched HLA in leukemia is a major mechanism of in vivo escape from T cell immunosurveillance following haploidentical hematopoietic stem cell transplantation (2009) (0)
Randomized phase III trial of haploidentical HCT with or without an add back strategy of HSV-TK donor lymphocytes in patients with high-risk acute leukemia. (2012) (0)
“Ex-vivo” gene therapy: Cell and tissue engineering (1995) (0)
NGR-hTNF plus chemotherapy as first-line therapy of non-small cell lung cancer (NSCLC). (2012) (0)
Abstract 748: Development and application of novelin silicomethods in the discovery and characterization of integrins antagonists (2010) (0)
Abstract 391: Both NGR and TNF portions of NGR-TNF contribute to tumor vessel specific homing and apoptosisin vivo (2010) (0)
9103 POSTER Phase II Trial of NGR-hTNF and Doxorubicin in Relapsed Small Cell Lung Cancer (SCLC) (2011) (0)
Infusions of HSV-TK genetically modified donor lymphocytes enable a wider use of partially mismatched allogeneic transplantation by reducing infection related mortality and improving survival in high risk acute leukemia. (2006) (0)
512. The Cytokine Release Syndrome Crucially Contributes to the Anti-Leukemic Effects of CD44v6 CAR-T Cells (2016) (0)
O111 - Fine-specificity analysis of HLA-A*02 restricted cytotoxic T lymphocytes specific for peptides from tumor associated antigens Mage-3 and Melan-A/MART-1 (1996) (0)
WT1 Transcripts Is a Powerful Leukemia Marker to Predict Early Relapse After Allogeneic Haematopoietic Stem Cell Transplantation. (2009) (0)
Human Gene Therapy: A New Beginning (1998) (0)
Grounds for Optimism (2007) (0)
Theoretical Availability of UCBT in High Body Weight Patients Who Received Haplo-SCT for High Risk Haematological Malignancies: Results of the Simulation of Search through BMDW According to International Guidelines (2008) (0)
Brain-directed gene transfer therapy for Tay-Sachs disease gives rice a wider distribution of the B-Hexosaminidase A (2002) (0)
NGR-derived isoDGR is a natural recognition motif of the RGD-binding site of αvβ3 integrin (2008) (0)
allogeneic stem-cell transplantation engineered donor lymphocytes after - Antitumor effects of HSV-TK (2013) (0)
Naive-derived memory stem T-cells: a novel promising platform for immune-gene therapy approaches (2012) (0)
R-CHOP preceded by blood-brain barrier permeabilization (BBBp) by NGR-tumor necrosis factor (NGR-hTNF) in patients with relapsed or refractory primary CNS lymphoma (rrPCNSL): First results of the “INGRID” phase II trial. (2018) (0)
Requirements for retroviral targeting of a suicide gene to alloreactive memory stem T cells for adoptive immunotherapy of leukemia (2008) (0)
Implementation of An Alternative Donor Option Is Prerequisite for a Good Intention-to-Treat (ITT) In Patients In Need of Allogeneic Transplantation: Analysis of 410 Patients (2010) (0)
Thymic renewal and antileukemic effect in adults after haploidentical transplantation and suicide gene therapy. (2010) (0)
O113 - Characterization of peptides with binding activity to HLA-B44 encoded by tumor associated antigen Mage-3 (1996) (0)
Changes in shedding of soluble tumor necrosis factor receptors (sR1/R2) and in dynamic MRI as early predictors of outcome with NGR-hTNF. (2013) (0)
Erratum to "Lentiviral Vector-Mediated Gene Transfer in T Cells from Wiskott-Aldrich Syndrome Patients Leads to Functional Correction". (2005) (0)
Phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), administered as single agent at low dose in patients with colorectal cancer refractory to standard regimens (2008) (0)
Abstract 4381: The novel direct-acting vascular targeting agent NGR-TNF exertsin vivoantitumor activity by inducing endothelial and tumor cell death in the absence of proangiogenic bone-marrow derived cell recruitment (2012) (0)
Predictive potential of angiogenic plasma biomarkers (PBs) in phase I trial with NGR-hTNF. (2010) (0)
111-P: Loss of Mismatched HLA in Family Haploidentical and Unrelated HSCT (2010) (0)
891. Correction of Established Neurologic Disease and Evidences of In Vivo Cross Correction in the Mouse Model of Metachromatic Leukodystrophy (2006) (0)
Epitope-Specific Typing (EST) for HLA-DPB1 Matching: Proof of Principle for an Innovative Approach to Unrelated Hematopoietic Stem Cell Donor Selection. (2006) (0)
Early and Effective Immune-Recovery by Gene-Engineered Lymphocytes after Haploidentical Transplantation for Leukemia Abate Late Transplant Mortality (2008) (0)
TCR-activation maintain an intact immune competence Human T lymphocytes transduced by lentiviral vectors in the absence of (2011) (0)
Cytotoxicity on tumor cells of human macrophages: functional status of tumor-associated effector cells. (1982) (0)
Method for labeling of eukaryotic cells by use of cell surface receptors as marker (1994) (0)
Monocytes Are Required for Both Optimal Anti-Leukemic Efficacy and the Cytokine Release Syndrome By CAR-T Cells: Lessons from an Innovative Xenotolerant Mouse Model (2016) (0)
Two doses of NGR-hTNF combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens: A phase II study. (2010) (0)
Rapid Detection of Pathogens Causing Sepsis in Neutropenic Hematologic Patients by a Multiplex PCR-Based Assay (2011) (0)
Gene Transfer Strategy Used to Treat Tay-Sachs Disease (2005), by Sabata Martino’s Research Group (2018) (0)
906. Successful functional correction of T cells from Wiskott-Aldrich syndrome patients with lentiviral vectors (2004) (0)
Effect of Related and Unrelated Donor Haematopoietic Stem-Cell Transplantation on Outcome in Adults With High Risk Hematological Disease: An intention-to-treat Analysis of 410 Patients at a Single Center Institution (2011) (0)
703. Development of RD-MolPack-trLNGFR/dCK.DM.S74E Stable Packaging Cells (2016) (0)
stimulating factor Chemotactic activity of recombinant human granulocyte colony (2013) (0)
Hematopoietic stem cell gene therapy for ADA-SCID (2008) (0)
T Cell Receptor Gene Transfer into Naive and Central Memory Lymphocytes by Lentiviral Vectors for a Safe and Effective Adoptive Immune Therapy of Leukemia (2008) (0)
A four-arm randomized phase II trial with NGR-hTNF given at low or high dose with or without doxorubicin in soft tissue sarcomas (STS). (2014) (0)
Phase II study of NGR-hTNF, a novel vascular targeting agent (VTA), as second-line therapy in malignant pleural mesothelioma (MPM) (2008) (0)
Early immune reconstitution and abrogation of GvHD after infusion of HSV-TK engineered donor lymphocytes after haplo-identical hemopoietic stem cell transplantation. (2004) (0)
Editing Human Lymphocyte Specificity for Safe and Effective Adoptive Immunotherapy of Leukemia. (2010) (0)
Phase II study of NGR-hTNF, a vascular targeting agent, in combination with doxorubicin in patients with relapsed small cell lung cancer (SCLC). (2010) (0)
Anti-metastatic activity of the tumor vascular targeting agent NGR-TNF (2015) (0)
Efficient gene transfer into primitive hematopoietic progenitors using a bone marrow microenvironment cell line engineered to produce retroviral vectors. (2004) (0)
Front-Line Chemotherapy with or without NGR-HTNF in Non-Small Cell Lung Cancer (NSCLC) (2012) (0)
metabolic defects deaminase (ADA)-deficient mice and corrects their immune and Ex vivo gene therapy with lentiviral vectors rescues adenosine (2012) (0)
Quantitative Real-Time PCR Detection of Wilms' Tumor Gene (WT1) Transcript in Autologous Peripheral Blood Stem Cell (PBSC) Products Predict the Risk of Acute Myeloid Leukaemia (AML) Relapse After Autologous Transplantation (ASCT). (2009) (0)
6066 Phase II study of two doses of NGR-hTNF, a vascular targeting agent (VTA), combined with capecitabine/oxaliplatin (XELOX) in colorectal cancer (CRC) patients failing standard regimens (2009) (0)
Long-Term Safety and Efficacy of Stem Cell Gene Therapy for ADA-SCID. (2006) (0)
IL-7 receptor expression identiﬁes suicide gene–modiﬁed allospeciﬁc CD8 (cid:1) T cells capable of self-renewal and differentiation into antileukemia effectors (2011) (0)
Leukemic Blasts Secondary to Myelodysplastic Syndromes Are Molecularly Programmed To Differentiate into Functionally Mature Dendritic Cells. (2007) (0)
Abstract 4258: Both NGR and TNF portions contribute to the biological activity of NGR-TNF vascular targeting agent in vivo (2011) (0)
Bone Marrow Transplantation for Immune Therapy (2003) (0)
Haploidentical Transplantation Outcome is Not Inferior to Standard Matched Related - Unrelated Donor Transplantation: An Intention-to-Treat Analysis of 611 Patients in 8-Years Experience at San Raffaele Scientific Institute (2013) (0)
Mechanism of thymic renewal after infusion of suicide gene-modified donor T cells after hematopoietic stem cell transplantation (HSCT) in adult patients. (2011) (0)
9. Hematopoietic stem cell based gene therapy for the treatment of metachromatic leukodystrophy: Towards clinical testing (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Claudio Bordignon?

Claudio Bordignon is affiliated with the following schools:

University of Milan
University of Verona
Vita-Salute San Raffaele University
University of Modena and Reggio Emilia
University of Siena